Transformative Evidence
Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin (CORE-001)
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
Videos
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
- Condition: Non Muscle Invasive Bladder Cancer
- Study ID: NCT04387461
Physician-Scientist Review Articles
State of the Evidence Review Articles
Conference Coverage
Conference Highlights Written by Physician-Scientist
Publications
Peer-Reviewed Journal Abstracts
Press Releases
Official Announcements on Clinical Developments